BNT162b2

E812198
COVID-19 vaccine Pfizer–BioNTech COVID-19 vaccine SARS-CoV-2 vaccine mRNA vaccine pharmaceutical product

BNT162b2 is an mRNA-based COVID-19 vaccine, co-developed by BioNTech and Pfizer, that became one of the first widely authorized vaccines against SARS-CoV-2.

Try in SPARQL Jump to: Surface forms Statements Referenced by

Observed surface forms (1)

Surface form Occurrences
Pfizer–BioNTech COVID‑19 vaccine 2

Statements (51)

Predicate Object
instanceOf COVID-19 vaccine ⓘ
Pfizer–BioNTech COVID-19 vaccine ⓘ
SARS-CoV-2 vaccine ⓘ
mRNA vaccine ⓘ
pharmaceutical product ⓘ
contains nucleoside-modified mRNA ⓘ
deliverySystem lipid nanoparticle ⓘ
encodesProtein SARS-CoV-2 S protein NERFINISHED ⓘ
SARS-CoV-2 spike glycoprotein NERFINISHED ⓘ
encodesRegion full-length prefusion stabilized spike protein ⓘ
hasAgeIndication adolescents ⓘ
adults ⓘ
children ⓘ
hasAlternativeName Comirnaty NERFINISHED ⓘ
Pfizer–BioNTech COVID-19 vaccine NERFINISHED ⓘ
hasATCCode J07BX03 ⓘ
hasCommonAdverseEffects fatigue GENERATED ⓘ
headache GENERATED ⓘ
injection site pain GENERATED ⓘ
myalgia GENERATED ⓘ
hasDeveloper BioNTech NERFINISHED ⓘ
Pfizer NERFINISHED ⓘ
hasDoseInterval 21 days between first and second dose ⓘ
hasDosingSchedule two-dose primary series ⓘ
hasFirstAuthorizationDate 2020-12-02 ⓘ
hasIndication prevention of COVID-19 in humans ⓘ
hasInitialAdultDose 30 micrograms mRNA ⓘ
hasInitialAdultDoseVolume 0.3 mL ⓘ
hasMechanismOfAction elicits cellular immune response to SARS-CoV-2 spike protein ⓘ
induces neutralizing antibodies against SARS-CoV-2 spike protein ⓘ
hasPrimaryInjectionSite deltoid muscle ⓘ
hasRareAdverseEffects myocarditis ⓘ
pericarditis ⓘ
hasRegulatoryApproval Conditional Marketing Authorization by European Medicines Agency ⓘ
Emergency Use Authorization by U.S. FDA NERFINISHED ⓘ
WHO Emergency Use Listing NERFINISHED ⓘ
hasReportedEfficacy approximately 95% efficacy against symptomatic COVID-19 in initial Phase 3 trial GENERATED ⓘ
hasRouteOfAdministration intramuscular injection ⓘ
hasStabilityAfterThawing limited stability at refrigerator temperatures ⓘ
hasStorageRequirement ultra-low temperature freezing ⓘ
hasStorageTemperature approximately −70 °C ⓘ
hasUSBrandName Comirnaty NERFINISHED ⓘ
hasUSFDAEUAdate 2020-12-11 ⓘ
hasUSFDALicensureDate 2021-08-23 ⓘ
isCoDevelopedBy BioNTech SE NERFINISHED ⓘ
Pfizer Inc. NERFINISHED ⓘ
targetsDisease COVID-19 NERFINISHED ⓘ
targetsVirus SARS-CoV-2 NERFINISHED ⓘ
vaccinePlatform mRNA ⓘ
wasFirstAuthorizedIn United Kingdom NERFINISHED ⓘ
wasKeyTrial Phase 3 trial NCT04368728 ⓘ

Referenced by (5)

Full triples — surface form annotated when it differs from this entity's canonical label.

BioNTech → developed → BNT162b2 ⓘ
Pfizer–BioNTech → notableWork → BNT162b2 ⓘ
Pfizer–BioNTech → developed → BNT162b2 ⓘ
Pfizer–BioNTech → developed → BNT162b2 ⓘ
this entity surface form: Pfizer–BioNTech COVID‑19 vaccine
Pfizer–BioNTech → hasRegulatoryApprovalFor → BNT162b2 ⓘ
this entity surface form: Pfizer–BioNTech COVID‑19 vaccine